Needham Reiterates Hold Rating on Hims and Hers (HIMS)

Needham analyst Ryan MacDonald reiterated a Hold rating on Hims and Hers (NYSE: HIMS).

The analyst commented: "Boy what a difference a year makes. HIMS emerged from the 2025 Super Bowl as a winner with their bold marketing strategy. However, fast-forward to 2026 and HIMS has been forced to retreat during the big weekend, halting sale of a new compounded semaglutide pill following scrutiny from the FDA, which led to HHS referring HIMS to the DOJ for an investigation into potential violations. While HIMS' decision has reportedly come following constructive convos with industry stakeholders, it is unknown if the potential legal/regulatory issues are resolved. At minimum, a lack of an oral GLP-1 denies HIMS a much-needed growth driver. However, continued FDA/DOJ pursuit could put HIMS' multi-hundred million dollar injectibles rev stream at risk as well. As a result, we remain on the sidelines given the heightened level of uncertainty."

For an analyst ratings summary and ratings history on Hims and Hers click here. For more ratings news on Hims and Hers click here.

Shares of Hims and Hers closed at $23.02 yesterday.

You May Also Be Interested In

• Waller: Recent Increases In Core Inflation Are Quite Broad
• JD.com, Inc (JD) PT Lowered to $37 at Macquarie ahead of earnings
• Cumberland Pharmaceuticals declares $1.50 special dividend after Apotex deal